MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,560K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from at the market offe...
Depreciation and amortization ex...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Operating lease right of use lia...
Accrued expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Amortization of debt discount and financing costs
-
-
0
0
Net loss
-4,160
11,896
-5,181
-10,823
Depreciation and amortization expense
438
-802
427
801
Stock-based compensation
157
-1,427
529
1,129
Change in fair value of other liabilities and derivatives
1
-132
100
-16
Prepaid expenses and other current assets
261
28
-118
156
Accounts receivable
-15
-
-
-
Accounts payable
74
1,156
-191
-733
Accrued expenses and other current liabilities
-275
727
264
-1,449
Operating lease right of use liability
-342
743
-304
-764
Net cash used in operating activities
-4,353
12,133
-4,238
-12,011
Purchases of machinery and equipment
33
-86
27
64
Net cash used in investing activities
-33
86
-27
-64
Proceeds from exercise of common stock warrants
-
-
0
0
Proceeds from issuance of noncontrolling interest in nova cell
-
-
0
-
Related party proceeds from issuance of loan payable
-
-
0
0
Repayment of principal on related party term notes payable
-
-
375
1,625
Proceeds from issuance of convertible notes payable
-
-
0
0
Repayment of principal on term notes payable
-
-
0
200
Proceeds from issuance of common shares and warrants per subscription agreement
-
-
0
-
Repayment of principal on related party bridge loan payable
-
-
0
200
Proceeds from issuance of promissory note
-
-
0
-
Repayment of convertible note payable
-
-
0
0
Payment of debt issuance costs
-
-
0
0
Proceeds from public offerings
-
-
6,090
6,573
Proceeds from warrant inducement financing
-
-
4,136
0
Proceeds from public offerings
0
5,369
-
-
Proceeds from registered direct offering
-
-
0
3,503
Proceeds from at the market offering
1,989
-
-
-
Proceeds from exercise of pre-funded warrants
5
0
2
3
Payment of financing costs
118
-554
344
381
Repayment of financing lease obligations
47
-19
29
34
Net cash provided by financing activities
1,829
-11,960
9,480
7,639
Effect of exchange rate changes on cash
-3
-13
0
6
Net decrease in cash and restricted cash
-2,560
246
5,215
-4,430
At beginning of the period
10,594
10,594
9,809
-
At end of the period
4,290
6,850
10,594
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from at the
market offering
$1,989K
Proceeds from exercise of
pre-funded warrants
$5K
(66.67%↑ Y/Y)
Net cash provided by
financing activities
$1,829K
(-76.06%↓ Y/Y)
Canceled cashflow
$165K
Net decrease in cash
and restricted cash
-$2,560K
(42.21%↑ Y/Y)
Canceled cashflow
$1,829K
Depreciation and
amortization expense
$438K
(-45.32%↓ Y/Y)
Stock-based compensation
$157K
(-86.09%↓ Y/Y)
Accounts payable
$74K
(110.10%↑ Y/Y)
Accounts receivable
-$15K
Change in fair value of
other liabilities and...
$1K
(106.25%↑ Y/Y)
Payment of financing
costs
$118K
(-69.03%↓ Y/Y)
Repayment of financing
lease obligations
$47K
(38.24%↑ Y/Y)
Net cash used in
operating activities
-$4,353K
(63.76%↑ Y/Y)
Canceled cashflow
$685K
Net cash used in
investing activities
-$33K
(48.44%↑ Y/Y)
Effect of exchange rate
changes on cash
-$3K
(-150.00%↓ Y/Y)
Net loss
-$4,160K
(61.56%↑ Y/Y)
Operating lease right of
use liability
-$342K
(55.24%↑ Y/Y)
Accrued expenses and
other current...
-$275K
(81.02%↑ Y/Y)
Prepaid expenses and
other current assets
$261K
(67.31%↑ Y/Y)
Purchases of machinery and
equipment
$33K
(-48.44%↓ Y/Y)
Buy us a coffee
Calidi Biotherapeutics, Inc. (CLDWW)
Calidi Biotherapeutics, Inc. (CLDWW)